AMGEN INC
AMGNPharma & biotechamgen.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Nov 4, 2026
Next reportFebruary 1, 2027after close · forecast 5.887 $/share
Revenue
$10.37B
▲ +8.5% vs prior year YoY
Net income
$3.86B
▲ +20.1% vs prior year YoY
EPS
7.08$
▲ +19.4% vs prior year YoY
Net margin
37.3%
▲ +3.6 pp vs prior year YoY
Revenue▲ +8.5%
Margins (% of revenue)GrossOperatingNet
Net income▲ +20.1%
EPS▲ +19.4%
Financial statements
View 10-Q filed November 4, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $9.09B | $8.15B | $9.18B | $9.56B | $9.87B | $8.62B | $10.05B | $10.37B | ▲ +8.5% |
| Gross profit | $5.97B | $5.18B | $6.17B | $6.47B | $6.89B | $5.87B | $7.24B | $7.58B | ▲ +17.0% |
| Operating income | $2.31B | $1.18B | $2.66B | $2.53B | $2.72B | $2.67B | $3.51B | $3.71B | ▲ +46.9% |
| Net income | $627.00M | $1.73B | $1.43B | $3.22B | $1.33B | $1.82B | $2.38B | $3.86B | ▲ +20.1% |
| R&Dnever filed | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | — | 3.20 $ | 2.65 $ | 5.93 $ | — | 3.34 $ | 4.37 $ | 7.08 $ | ▲ +19.4% |
| Margins (% of revenue) | |||||||||
| Gross | 65.7 % | 63.6 % | 67.2 % | 67.8 % | 69.8 % | 68.2 % | 72.0 % | 73.1 % | ▲ +5.4 pt |
| Operating | 25.4 % | 14.5 % | 28.9 % | 26.4 % | 27.6 % | 30.9 % | 35.0 % | 35.8 % | ▲ +9.4 pt |
| Net | 6.9 % | 21.2 % | 15.6 % | 33.7 % | 13.5 % | 21.1 % | 23.6 % | 37.3 % | ▲ +3.6 pt |
| Balance sheet | |||||||||
| Assets | $91.84B | $89.37B | $87.90B | $90.14B | $90.59B | $92.50B | $95.64B | $96.05B | ▲ +6.6% |
| Liabilities | $85.96B | $83.16B | $80.47B | $80.52B | $81.93B | $83.31B | $83.95B | $81.70B | ▲ +1.5% |
| Equity | $5.88B | $6.21B | $7.43B | $9.62B | $8.66B | $9.19B | $11.69B | $14.35B | ▲ +49.2% |
| Cash | $11.97B | $8.81B | $8.03B | $9.45B | $9.13B | $12.04B | $13.99B | $13.19B | ▲ +39.7% |
| Capital | |||||||||
| Shares outstanding | 537.20M | 537.71M | 538.36M | 538.48M | 539.07M | 539.71M | 540.63M | 540.91M | ▲ +0.5% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.